Vertex Pharmaceuticals Inc (VRTX)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$435.00

Buy

$505.28

arrow-up$0.52 (+0.11%)

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
Prices updated at 03 Apr 2025, 11:25 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-down-5.97%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Income statement

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
2,489m3,048m4,163m6,206m7,574m8,931m9,869m11,020m
2,214m2,638m3,615m5,469m6,670m7,850m8,607m9,490m
393m664m1,202m2,869m2,779m4,365m4,308m4,395m
15.7821.7928.8746.2436.6948.8843.6539.88
263m2,097m1,177m2,712m2,342m3,322m3,620m-536m
115m745m1,560m3,285m2,918m4,436m4,605m486m
Sales, General and administrative496m558m659m771m840m945m1,137m1,464m
Interest expenses69m72m59m58m62m55m44m31m
Provision for income taxes-107m-1,487m218m405m388m910m760m784m
Operating expenses1,821m1,974m2,413m2,600m3,891m3,485m4,300m5,095m
Income before taxes-16m600m1,395m3,117m2,730m4,232m4,380m249m
Net income available to common shareholders263m2,096m1,177m2,712m2,342m3,322m3,620m-536m
1.068.244.5810.449.0912.9714.05-2.08
Net interest income-58m-34m5m-36m-57m90m571m568m
Advertising and promotion--------
Net investment income, net--------
Realised capital gains (losses), net--------
Total benefits, claims and expenses--------
Earnings per share (diluted)1.048.094.5110.299.0112.8213.89-2.08
Free cash flow per share2.11924.10415.242311.30347.351914.767116.1506-5.2227
Book value/share7.072311.388820.283931.295837.451850.696564.078860.8347
Debt equity ratio0.2878380.1311210.1023570.1023970.0878420.0582420.0412220.10099

Balance sheet

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
Current assets2,649m3,843m4,823m8,133m9,561m13,235m14,144m9,596m
Current liabilities807m1,120m1,335m1,878m2,142m2,742m3,547m3,565m
Total capital2,029m4,435m6,085m8,687m10,100m13,913m17,580m16,410m
Total debt606m591m653m932m934m900m808m1,750m
Total equity2,029m4,435m6,085m8,687m10,100m13,913m17,580m16,410m
Total non current liabilities--------
Loans--------
Total assets3,546m6,246m8,318m11,752m13,433m18,151m22,730m22,533m
Total liabilities--------
Cash and cash equivalents1,665m2,650m3,109m5,988m6,795m10,504m10,369m4,570m
Common stock253m255m259m260m254m257m258m257m

Cash flow

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
Cash at beginning of period1,184m1,668m2,658m3,121m5,989m6,800m10,512m10,372m
Cash dividends paid--------
586m1,175m1,494m2,994m2,409m3,925m3,279m-978m
Investments (gains) losses-438m-202m-1,235m99m-341m-321m-3,142m-3,770m
1,665m2,658m3,121m5,989m6,800m10,512m10,372m4,572m
Net income--------
845m1,270m1,569m3,254m2,644m4,130m3,537m-493m
-259m-96m-75m-260m-235m-205m-258m-485m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.